Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
With
Bristol-Myers Squibb
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Type 2 Diabetes
Patients with HbA1c ≥7.5% and ≤10.5% and who are on a stable insulin regimen of at least 30 IU of injectable insulin per day either without any other oral antidiabetic drug or with a stable dose of oral antidiabetic drugs
You may not be if
Type 1 Diabetes
Treatment with more than two additional oral antidiabetic drugs
Moderate and severe renal (kidney) failure or dysfunction
Clareo Health | Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin
